| COUNTRY |
FUNDING BODY |
TYPE OF STUDIES |
AMOUNT AVAILABLE |
DEADLINE |
Austria |
Austrian Science Fund |
Prevention, mitigation, detection, containment of epidemics, including SARS CoV2 and impact of current epidemic |
Not specified |
30-09-2020 |
Czech Republic |
Grant Agency of the Czech Republic, collaboration with Austrian Science Fund – International projects |
As stipulated in the FWF call above, International projects must also focus on: Prevention, mitigation, detection, containment of epidemics, including SARS CoV2 and impact of current epidemic. |
Not Specified |
30-09-2020 |
Czech Republic |
Czech Technology Agency |
Innovative solutions for combating the current epidemic and improving preparedness in future outbreaks |
40 M CZK per project |
31-12-2020 |
France |
National Research Agency (ANR) – “RA-COVID19” |
Operational/interventional studies for prevention or diagnostics, clinical trials, vaccine trials, Epidemiology and surveillance, OneHealth approaches, socio-economic impact studies |
Epidemiology, Physiopathogenesis, Infection prevention and control, Ethics and social dynamics, Global issues of the Covid-19 epidemic. |
28-10-2020 |
France |
BPI France/ Secretariat Général Pour L’Investissement |
Public private partnerships for developing and producing therapeutic solutions for COVID19, including clinical trials |
4M to 50 M € per project |
30-09-2020 |
Germany |
German Research Foundation |
Prevention, early detection, containment and investigation of the causes, impacts and management of epidemics and pandemics including but not exclusively SARS CoV 2 |
Not specified |
Letter of intent: 01-07-2020 / Final submission: 01-09-2020 |
Germany |
Federal Ministry of Education and Research |
Vaccine development and clinical trials |
NA |
31-12-2020 |
Ireland |
Science Foundation of Ireland/ Enterprise Ireland and IDA Ireland |
Innovative solutions for contact tracing, frontline care, diagnostics, epidemiological tools, monitoring of control measures, mitigation of crisis on a sanitary, social and economic level, and more |
Funding requests will depend on the specific needs of the project. |
24-08-2020 |
Italy |
Area Science Park and ARGO System |
Medical-health fields, artificial intelligence algorithms and scientific data extraction – using the ORFEO data Center |
400K € total |
31-07-2020 |
Malta |
Malta Council for Science and Technology & Malta Enterprise |
Epidemiology, Basic Science, Clinical Research, Social Sciences, IT, |
5,3 M € total |
30-12-2020 |
Norway |
Norwegian Cancer Society |
Incidence/prevalence, consequences and treatment of cancer patients with COVID19 in Nordic countries |
200K €/project |
01-09-2020 |
Spain |
Banco Santander/Crue Universidades Espanolas |
Big data analysis, clinical research, basic science, socio-economic impact, innovative products and solutions for crisis mitigation |
8,5 M € Total |
Rolling applications until 18 December 2020 |
Sweden |
Swedish Research Council |
Exceptional redirection of ongoing grants to focus on COVID19 |
No more than 1/3 of amount yearly allocate |
Ongoing – requires an authorization |
Sweden |
Vinnova |
Innovation projects in the health field that dampen the prevalence and effects of the covid-19 pandemic |
SEK 5 million/project |
18-08-2020 |
Switzerland |
ETH Zurich |
Research in all research fields, in collaboration with Asian nations, for the fight against the COVID19 epidemic. |
25 kCHF per project |
30-08-2020 |
United Kingdom |
British Heart Foundation |
Clinical research on cardiovascular disease and COVID19 |
Not specified – applications must align with UK COVID19 priorisation process |
Rolling applications evaluated weekly |
United Kingdom |
GOSH / Sparks foundation |
COVID19 and rare diseases in children |
250K £/project |
19-08-2020 |
United Kingdom |
UK MRC |
Virology, Immunity and Pathophysiology, Diagnostics, Epidemiology, PPE and other protective material, Public Health, Clinical Research, Vaccines, Health Care and Delivery |
Variable depending on project needs |
Rolling call - 1 Apr 2021 |
United Kingdom |
NIHR |
Urgent Public Health Research – through National Priorisation Process |
NA |
Rolling applications |
United Kingdom |
NIHR |
Solutions for low and middle-income countries – clinical trials, epidemiology, prevention, diagnostics and more |
1M£/project |
10-08-2020/28-09-2020 |
United Kingdom |
UK Research and Innovation/ Newton Fund |
Innovative solutions to gather critical data, support manufacture or wide scale adoption of an intervention, better understand and mitigate impact of the epidemic in Low and Middle Income countries |
80% of the full economic cost |
none - apply at any time |
United Kingdom |
UK Research and Innovation |
Innovative solutions to gather critical data, support manufacture or wide scale adoption of an intervention, better understand and mitigate impact of the epidemic |
80% of the full economic cost |
none - apply at any time |
Pan European |
Partnership for Advanced Computing in Europe (PRACE) |
Projects requesting computer resources for: epidemiology, bioinformatics, bio-simulation, biomolecular analysis, other studies to mitigate the epidemic |
Resources requested reviewed for each proposal |
Open until further notice |
Pan European |
EDCTP |
Training and capacity building opportunities on epidemiology to fight epidemics in Africa, in support of the African CDC – COVID19 focus is highly recommended |
50 K €/ student |
30-07-2020 |
Pan European |
Interreg- Northern Periphery and Arctic Program |
Clinical aspects of COVID19, health and wellbeing of populations during and after the pandemic, technological solutions, citizen engagement, economic impact, and more |
45K € per project |
30-09-2020 |
Pan European |
TRANSVAC |
Support vaccine-related projects currently in the preclinical phase of development |
NA |
04-08-2020 |
International |
GILEAD |
Solutions for long term care, real world safety and effectiveness of remdesivir, viral kinetics, care of high-risk patients, and more |
250K USD/project – although exceptions can exist |
03-08-2020 |
International |
CEPI |
Accelerating vaccine development and manufacturing Phase II - vaccines striving for licensure/emergency authorization in 12-18 months or less and, to ensure the availability of sufficient doses by 2021 |
NA |
28-09-2020 |
